Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Tirzepatide Recent Developments In September 2025, Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first Phase III trial to evaluate the safety and efficacy of MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both
The length of the infusion is also important
PMID: 40756949 (view on PubMed) Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats
Pack it in your carry-on with your prescription documentation, declare it at the security checkpoint, and bring any syringes and needles alongside the medication
NICE NG28 emphasises that HbA1c targets should be individualised, taking into account patient preferences, comorbidities, and risk of hypoglycaemia, rather than applying a single universal threshold
